Literature DB >> 10440417

Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.

M Savcic1, J Hauert, F Bachmann, P J Wyld, B Geudelin, R Cariou.   

Abstract

Clopidogrel, a potent novel platelet ADP-receptor antagonist, induces a significant inhibition of ADP-induced platelet aggregation. Maximum inhibition of 40 to 50% is observed 2 to 5 hours after a single 400 mg dose. The same level of inhibition is achieved with 75 mg once daily at steady state, i.e., after 3 to 7 days of repeated dosing. Based on these data, two studies were undertaken to investigate whether a treatment regimen comprising a large initial dose (loading dose) of clopidogrel, followed by daily doses of 75 mg, might provide a sustained steady-state level of inhibition of platelet aggregation induced by 5 microM of ADP within hours after first dosing. In one study, 10 healthy male subjects received a 375 mg loading dose of clopidogrel on day 1, then daily doses of 75 mg from day 2 to day 10. Mean inhibition of platelet aggregation, already significant at 30 minutes, reached 55+/-8.2% (+/-SEM) at 60 minutes, and a maximum of 80+/-3.6% at 5 hours. No further significant change was observed between 5 hours and 24 hours, and from day 2 through day 10 with subsequent daily doses of 75 mg. In the second study, conducted according to a randomized, single-blind design, four parallel treatment groups of nine healthy male subjects received a loading dose of 75 mg, 150 mg, 225 mg, or 300 mg of clopidogrel on day 1, respectively, and 75 mg once daily from day 2 to day 5. Mean (+/-SD) inhibition of platelet aggregation over the 2 to 24 hours post-loading dose period was 22+/-14.5%, 21+/-13.4%, 35+/-20.6% and 31+/-13.3%, respectively. On day 5, it was 48+/-14.7%, 33 +/-14.1%, 51+/-15.7% and 40+/-10.9% for the 75, 150, 225 and 300 mg loading dose groups, respectively. The smallest day 1 to day 5 difference was observed for the 300 mg group and the largest for the 75 mg group, indicating that the development of the full inhibitory effect of clopidogrel was faster with the loading doses higher than with 75 mg, and fastest with the 300 mg loading dose. These data and those of previous studies indicate that a dose of 300 to 400 mg produces a rapid onset of the pharmacodynamic action of clopidogrel, with levels of inhibition close to steady-state reached within 2 hours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440417

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  30 in total

Review 1.  [Review of plasma anti-aggregants and their indications in primary care. Eight years later].

Authors:  M Blasco Valle; J F Lucía Cuesta
Journal:  Aten Primaria       Date:  2003-03-15       Impact factor: 1.137

Review 2.  Transfer for primary angioplasty: who and how?

Authors:  M Dalby; G Montalescot
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

3.  Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.

Authors:  Serkan Cay; Goksel Cagirci; Sinan Aydogdu; Yucel Balbay; Nihat Sen; Orhan Maden; Ahmet D Demir; Ali R Erbay
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 4.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Oral clopidogrel load in aspirin-resistant capsular warning syndrome.

Authors:  Christopher D Fahey; Mark J Alberts; Richard A Bernstein
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Role of platelet α2-adrenoreceptor in biological low response to Clopidogrel for patients with non cardioembolic ischemic stroke or transient ischemic attack.

Authors:  Jérôme Varvat; Magali Epinat; Aurélie Montmartin; Sandrine Accassat; Claire Boutet; Arnauld Garcin; Guorong Li; Fabrice Malergue; Céline Chapelle; Silvy Laporte; Pierre Garnier; Claude Lambert; Nora Mallouk; Patrick Mismetti
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 7.  Clopidogrel: a review of its use in the prevention of atherothrombosis.

Authors:  B Jarvis; K Simpson
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.

Authors:  Rui Liu; Zi-Yi Zhou; Yi-Bei Chen; Jia-Li Li; Wei-Bang Yu; Xin-Meng Chen; Min Zhao; Yuan-Qi Zhao; Ye-Feng Cai; Jing Jin; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 9.  Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Authors:  Thomas Lenz; Amy Wilson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Complications of Neuroform stent in endovascular treatment of intracranial aneurysms.

Authors:  Abutaher M Yahia; Vickie Gordon; John Whapham; Ali Malek; J Steel; Richard D Fessler
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.